Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 16, 2018

View Archived Issues

Microbiome affects rotavirus vaccine immunogenicity

TAC versus CAR

RAPTA-T pretreatment enhances tumor vascular function and cisplatin uptake in pleural mesothelioma

Discovery of a biomarker that correlates with psychopathy and cognition in schizophrenia

Identification of a gene that drives progression and metastases in KRAS-driven lung cancer

Preclinical studies identify a potential drug target for the treatment of neuroblastoma

First patient treated in Escalier Biosciences' phase I/IIa study of ESR-114

Entasis announces positive topline phase II data for ETX-2514 plus sulbactam in patients with cUTI

Brain immune cells mediate arthritic joint pain

IND approval received in China for phase Ib/III study of CAN-017 as treatment of ESCC

Hefei Institutes of Physical Sciences divulges EZH2 inhibitors

Proteasome inhibitors patented by Chengdu Origin Biotechnology

Shanghai Longwood Biopharmaceuticals identifies hepatitis B caspid assembly inhibitors

Nuclear receptor ROR-gamma inverse agonists discovered at Genfit

Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical describe TLR7 agonists

First patients dosed in phase I/II study of TLC-590 for postsurgical pain management

BHV-0223 reduces anxiety in proof-of-concept trial

Kalydeco approved in U.S. for cystic fibrosis in patients aged 12 to < 24 months

Phase II trial of AG-013 in oral mucositis resumes

Cabotegravir/rilpivirine regimen shows noninferiority to three-drug regimen for HIV infection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...